Pmh39: Depression and Fibromyalgia:treatment and Cost When Diagnosed Separately or Concurrently

Robinson, Rachel; Birnbaum, HG; Sisitsky, Tammy; Greenberg, Phil; Wolfe, Fred

doi:10.1016/s1098-3015(10)64241-6

Cited by 30 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Selection of comorbid conditions was based on prior research that identified potential comorbid conditions. 3,8,9 The diagnosis of each comorbidity was not necessarily a first occurrence of that condition. The Charlson Comorbidity Index (CCI) was constructed according to the definition provided by Deyo et al 24 …”

Section: Definition Of Medical Comorbiditiesmentioning

confidence: 99%

Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss

White

Birnbaum

Kaltenboeck

et al. 2008

Journal of Occupational &Amp; Environmental Medicine

153

185

View full text Add to dashboard Cite

• Compare prevalence rates of common comorbid conditions in employees diagnosed as having fibromyalgia (FM) or osteoarthritis (OA).• Identify trends in the use of medical care and prescription drugs by employees having FM or OA, as compared to control subjects.• Contrast total dollar costs and their components-medical costs, drug costs, and indirect costs of time lost from work-in employees with FM, those with OA, and control employees having neither of these disorders. ($10,199) approached OA costs ($10,861, P ϭ 0.3758) Med. 2008;50:13-24)

show abstract

Section: Definition Of Medical Comorbiditiesmentioning

confidence: 99%

Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss

White

Birnbaum

Kaltenboeck

et al. 2008

Journal of Occupational &Amp; Environmental Medicine

153

185

View full text Add to dashboard Cite

show abstract

“…Patients with FMS have high rates of medical care use with associated high expenditures (3)(4)(5)(6)(7)(8)(9), likely due to a continuing search for relief from chronic soft tissue pain, fatigue, and sleep disturbance (10 -12). Surveys have documented that complementary and alternative medicine (CAM) therapies are used by most patients with FMS in their search for relief; several reports have estimated that Ͼ90% of patients with FMS use CAM (1,13,14), many seeing CAM providers such as massage therapists (range of use 44 -53% of patients with FMS), chiropractors (37-47%), acupuncturists (11-22%), and naturopathic physicians (37%) (13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Use of complementary and alternative medicine providers by fibromyalgia patients under insurance coverage

Lind¹,

Lafferty²,

Tyree³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…The degree of disability and the number of comorbidities are strongly associated with costs (6). From a provider perspective, given the estimated prevalence of FMS of ϳ3.4% in women and ϳ0.5% in men (7), FMS is expensive and is associated with a high burden to society (8)(9)(10)(11)(12). The differential diagnosis of muscular pain is extensive, and, given the well-known frequency of such symptoms in the population, it is a frequent source of concern for general practitioners (GPs).…”

mentioning

confidence: 99%

Health economic consequences related to the diagnosis of fibromyalgia syndrome

Annemans

Wessely

Spaepen³

et al. 2008

Arthritis & Rheumatism

120

View full text Add to dashboard Cite

Objective. To evaluate the use and costs of medical resources before and after a diagnosis of fibromyalgia syndrome (FMS) in a large primary care population in the UK.Methods. We applied an existing data set for medical resource use among patients with a coded diagnosis of FMS. The observed quantities of 157 types of medical resource use before and after the diagnosis of FMS were multiplied by unit costs in order to calculate the cost of care (general practitioner [GP] visits, drugs, referrals, and diagnostics) within the National Health Service, excluding hospital costs. Costs before diagnosis were used in a trend analysis to predict later costs, assuming the diagnosis had never been made, and these predicted costs were compared with the observed costs after diagnosis.Results. Following a diagnosis of FMS, a decrease in costs as compared with the predicted trend was observed. In the 4 years after diagnosis, the average difference between the predicted and observed cost was £66.21 per 6 months per patient. This suggests that making the diagnosis leads to savings and a decrease in resource use. The main effect was observed for tests and imaging (£24.02 per 6 months), followed by pharmaceuticals (£22.27), referrals (£15.56), and GP visits (£4.36). Conclusion.Failure to diagnose a true case of FMS has its own costs, largely in excess GP visits, investigations, and prescriptions.

show abstract

Pmh39: Depression and Fibromyalgia:treatment and Cost When Diagnosed Separately or Concurrently

Cited by 30 publications

References 0 publications

Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss

Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss

Use of complementary and alternative medicine providers by fibromyalgia patients under insurance coverage

Health economic consequences related to the diagnosis of fibromyalgia syndrome

Contact Info

Product

Resources

About